Abstract 19076: The Association of Soluble Fms-Like Tyrosine Kinase-1 (sflt-1) With Risk of Heart Failure and Atrial Fibrillation: Insights From the Dallas Heart Study

• Published in: Circulation (New York, N.Y.) N.Y.), 2023-11, Vol.148 (Suppl_1)
• Main Authors: Patel, Lajjaben, Subramanian, Vinayak, Nagori, Aditya, Pandey, Ambarish, Mauricio, Rina
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.148.suppl_1.19076

Abstract only Introduction: sFlt-1 has emerged as a biomarker of cardiovascular disease (CVD). However, its role in the development of incident non-atherosclerotic CVD (atrial fibrillation and heart failure) among a multi-ethnic community-dwelling cohort is not known. Methods: Participants from the Dallas Heart Study with available sFlt-1 measures at baseline were included. The primary outcome of interest was a composite of incident Heart Failure (HF), Atrial Fibrillation (AF), and death, and secondary outcome was a composite of recurrent HF, AF or death. The clinical events were adjudicated by a blinded end-point committee. Adjusted Cox proportional hazard models and Anderson Gill models were used to determine the association of sFlt with composite outcomes adjusting for traditional CV risk factors (diabetes, hypertension, hyperlipidemia, smoking, and BMI). Results: The study included 2907 participants (mean age 43.8 yrs, female 57%, median sFLt level 0.46 ng/mL). Participants with higher s-flt levels were older and had a higher proportion of traditional CV risk factors (Q1 vs Q4: 43 yrs vs 46 yrs, HTN 29.9% vs. 38.3%; DM 8.7% vs. 14.3%). Over a median follow-up of 14 years, the primary composite outcome occurred in 323 participants. In unadjusted analysis, sFlt was associated with a higher incidence of the primary composite outcome (HR [Q1 vs. Q4] 95%CI = 2 [1.4-2.7]; p